4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predicting tumor response to therapy, announced a collaboration with Daiichi Sankyo to develop next-generation predictive biomarkers in an antibody drug conjugate (ADC) clinical development program. This collaboration brings together 4D Path?s ability to compute biologically grounded, physics-informed treatment predictive biomarkers from routine pathology specimens with the ADC innovation leadership of Daiichi Sankyo. Under the collaboration, 4D Path will apply its proprietary Q-Plasia OncoReader (QPOR) platform to standard Hematoxylin and Eosin (H&E)-stained tumor biopsy slides to compute interpretable, quantitative biomarkers associated with cell-cycle deregulation and tumor microenvironment dynamics.
These biomarkers will be evaluated for their ability to identify patients most likely to benefit from the select ADC, helping enable more precise, non-invasive, and cost-effective patient selection, potentially improving response rates and accelerating clinical trials. This approach is designed to be compatible with both retrospective analyses of archived clinical specimens and prospective evaluation in ongoing and future studies. The collaboration is expected to also generate functional mechanistic insights into tumor-specific patterns of response and resistance?helping illuminate how biological context may interact with ADC designs.
By transforming routine pathology images into actionable, physics-informed collective tumor state variables, the agreement aims to enrich translational understanding while supporting more personalized and effective treatment strategies. This collaboration underscores the industry-wide shift toward AI-driven, image-based biomarkers that can be deployed at scale using standard-of-care specimens?supporting faster, more confident treatment decisions and improving the probability of success in clinical development.
